Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03504579 · ClinicalTrials.gov registry record · NA

Rt-fMRI Neurofeedback and AH in Schizophrenia

A NA study of Schizophrenia and Neurofeedback, sponsored by Harvard Medical School (HMS and HSDM).

Completed
Registry status
NA
Development phase
25
Enrollment target
1
Study location

NCT03504579 is a NA study of Schizophrenia and Neurofeedback that has completed, run by Harvard Medical School (HMS and HSDM). The registered enrollment target is 25 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03504579, a NA study of Schizophrenia and Neurofeedback, has completed, sponsored by Harvard Medical School (HMS and HSDM).

COMPLETED
Registry status
NA
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

Auditory hallucinations in schizophrenia are one of the major symptoms of this disease and a major source of psychological discomfort. They are often difficult or impossible to treat with existing methods. This study will test the use of real-time fMRI neurofeedback to mitigate auditory verbal hallucinations in patients whose hallucinations are resistant to medication. Half of the patients will receive real time fMRI neurofeedback from a brain region involved in auditory hallucinations and half will receive it from motor cortex.

Interventions

  • OTHER rt-fMRI neurofeedback

Study Locations (1)

Massachusetts

  • Veterans Administration Health Care System - Brockton

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2018-03-01
Est. Completion 2022-06-30
Phase NA

What the Registry Record Tells You About NCT03504579

The ClinicalTrials.gov registry entry for NCT03504579 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (89% lower). The listed sponsor is Harvard Medical School (HMS and HSDM), which has 26 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which rt-fMRI neurofeedback is the first listed.

NCT03504579 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03504579 about?

NCT03504579 is a clinical study titled "Rt-fMRI Neurofeedback and AH in Schizophrenia". Auditory hallucinations in schizophrenia are one of the major symptoms of this disease and a major source of psychological discomfort. They are often difficult or impossible to treat with existing methods. This study will test the use of real-time fMRI neurofeedback to mitigate auditory verbal hallu...

What is the current status of trial NCT03504579?

This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2018-03-01. Estimated completion is 2022-06-30.

What conditions does trial NCT03504579 study?

This clinical trial studies the following conditions: Schizophrenia, Neurofeedback, Audio Visual Hallucinations, Superior Temporal Gyrus.

What interventions are being tested in trial NCT03504579?

The interventions under investigation include: rt-fMRI neurofeedback (OTHER).

Who is sponsoring clinical trial NCT03504579?

This trial is sponsored by Harvard Medical School (HMS and HSDM), which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03504579 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.